Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- Definitions and measurement of treatment coverage
- Mass drug administration (MDA)
- MDA is delivered via different distribution platforms
- Elements for a strong delivery platform and population willingness
- WHO coverage definitions
- Program coverage
- National coverage
- Disease specific thresholds for sufficient coverage
- How treatment coverage is measured
- Comparing reported to surveyed coverage
- Example from Indonesia: LF reported vs. surveyed coverage (2015)
- Why coverage matters
- The path to elimination
- Lessons from Guinea worm
- What we know about who is and is not being reached
- Reasons for not receiving treatment
- Scenario 1
- Scenario 2
- Scenario 3
- Reasons for low reported coverage – across 19 ENVISION supported countries (FY17)
- Indonesia – LF MDA reported and surveyed coverage (2015)
- Indonesia – reason for not ingested drugs, coverage survey (2017)
- Gender equity in MDA
- Some populations are often missed
- Approaches and tools to improve coverage
- Urban MDA in Port-au-Prince, Haiti
- Reaching nomad populations in Tanzania
- Benin: lessons learnt on reaching school children for schistosomiasis MDA
- Source of many NTD programmatic tools
- Coverage related measurement tools
- Tools that support use of existing data to identify who may have been missed
- Tools for planning improved MDA
- Tools for managing AEs and reaching urban populations
- Thank you
Topics Covered
- Mass drug administration
- Treatment coverage
- Distribution platforms
- Delivery of MDA
- Elements for a strong delivery platform and population willingness
- Geographical coverage
- National coverage
- Program coverage
- Reasons for low reported coverage
- Tools for planning improved MDA
Links
Series:
- Neglected Tropical Diseases
- Periodic Reports: Advances in Clinical Interventions and Research Platforms
Categories:
Therapeutic Areas:
External Links
Talk Citation
Baker, M. (2022, July 31). Understanding treatment coverage in mass drug administrations [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/HRCR5958.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. Margaret Baker has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
HSTalks is pleased to grant unrestricted complimentary access to all lectures in the series Neglected Tropical Diseases. Persons not at a subscribing institution should sign up for a personal account.
Other Talks in the Series: Neglected Tropical Diseases
Other Talks in the Series: Periodic Reports: Advances in Clinical Interventions and Research Platforms
Transcript
Please wait while the transcript is being prepared...
0:00
Hello. My name is Maggie Baker.
I am an associate professor
at Georgetown University.
I have worked at the
global level for
the last few years
on research and
on USAID-funded entity
projects RTI International.
I also still really value
the foundational experience
that I had on NTDs,
working embedded
within ministries of
health and their
national LF programs.
First in Vanuatu in
the south Pacific,
and then the Dominican Republic.
In this presentation,
I want to bring together a
wide range of experiences
that have been shared
by people working in
NTD endemic countries
on the front line
and presented at conferences
and publications.
0:42
In this talk, I'm going to cover
the definitions of measurement
of treatment coverage,
why coverage matters,
what we know about who is and
who is not being reached,
and approaches and
tools that can
be used to improve coverage.
0:58
Starting with definitions and
measurement of
treatment coverage.
1:03
Mass Drug Administration (MDA)
means providing
treatments usually,
but not only, in the
form of tablets,
with the goal of bringing down
disease and infection
to very low levels.
Thus, eliminating the
suffering of hundreds of
the world's poorest and most
marginalized populations.
Just like with the
COVID vaccine,
the goal is often to
treat entire populations
living in places at risk,
from the very young to the old.
1:32
Mass Drug Administration or MDA
is delivered through different
distribution platforms.
On the left, this
drug distributor
is going house to house,
giving treatment to all
persons in all houses
within the area she
has been assigned.
In the top right,
you see the treatments
being delivered through
what is referred to as
a fixed post or booth.
These are temporary
spots set up around
the community to
which people are
asked to come to be treated.
Then schools are
also often used,
especially for
schistosomiasis treatments,
which target mainly
school age children.
This figure shows the
many different elements